Management of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer patients: beyond endocrine therapy.
APA
Wang PH, Lai JI, et al. (2026). Management of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer patients: beyond endocrine therapy.. Journal of the Chinese Medical Association : JCMA, 89(2), 101-102. https://doi.org/10.1097/JCMA.0000000000001331
MLA
Wang PH, et al.. "Management of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer patients: beyond endocrine therapy.." Journal of the Chinese Medical Association : JCMA, vol. 89, no. 2, 2026, pp. 101-102.
PMID
41457328
같은 제1저자의 인용 많은 논문 (5)
- The impact of brain metastases on outcome in metastatic breast cancer and extensive-stage small cell lung cancer.
- Chemoresistance in ovarian cancer (I).
- Mirvetuximab soravtansine-Gynx (MIRV) for treating platinum-resistant recurrent ovarian cancer.
- Genomic insights for neuroendocrine prostate cancer.
- [Functional rhinoplasty for nasal traumatic deformity].